Aprea Therapeutics (APRE) Stock Analysis

What Aprea Therapeutics does

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Key metrics

ETFs linked to APRE

Broad-market and Healthcare sector ETFs an investor holding Aprea Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how APRE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Aprea Therapeutics?

Aprea Therapeutics trades under the ticker APRE on NASDAQ.

Which exchange is APRE listed on?

APRE is listed on NASDAQ.

What sector does Aprea Therapeutics operate in?

Aprea Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze APRE in a portfolio?

PortView shows APRE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.